12 results about "Osseous metastasis" patented technology

The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefor, and use thereof. The present invention has discovered a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy which can accurately prevent tumor metastasis on the basis of the source, and can avoid drug resistance and biochemical drug resistance. On this basis, the present invention designs a physical killing nanomaterial targeting tumor-osteoclast conjugates, the nanomaterial being a bone targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively concentrated in bone tissue; when tumor cells are activated, the acid secretion function of tumor-related osteoclasts in nearby tumor-osteoclast conjugates which are in contact with the tumor cells triggers the carbonate compound to generate carbon dioxide gas and promotes the release of the phosphate compound, which forms calcium phosphate crystals with calcium ions so as to kill nearby tumor cells, thus achieving a specific very-early tumor metastasis inhibition effect.

The invention provides a method and a device for automatically segmenting and positioning a bone metastatic tumor in a bone scanning image and a computer program. The method comprises the following steps of: reading an original image in bone scanning image data; and inputting the original image into a pre-trained bone metastasis tumor segmentation and positioning model, automatically segmenting and positioning a bone metastasis tumor focus in the original image, and outputting focus segmentation results from channels corresponding to different body parts, the bone metastatic tumor segmentation and positioning model is a single model architecture based on a convolutional neural network and an attention mechanism. The technical scheme provided by the invention has high-precision focus segmentation and positioning capability, enhanced model generalization capability and multi-task joint learning optimization performance, and the focus recall rate tested by applying the scheme reaches 90.2%, the focus accuracy reaches 84.5%, the focus position positioning accuracy reaches 98.4%, and the focus position positioning average AUC reaches 96.1%.

The present invention relates to the field of radiopharmaceutical chemistry, and more particularly to a radioactive probe that targets fibroblast activation protein (FAP), a preparation method, and applications thereof. The structural formula of the compound targeting FAP provided by the present invention is: #imgabs0#. This compound possesses excellent radionuclide labeling properties. The resulting radioactive probe, a FAP inhibitor, can simultaneously target tumor-associated fibroblast activation protein (FAP) and bone metabolism-related targets, thereby improving diagnostic accuracy and specificity, increasing retention time and effectiveness, and enhancing treatment outcomes. This allows for more comprehensive diagnosis and evaluation of tumors and bone metastases, and is particularly suitable for patients with both primary tumors and bone metastases.

This invention discloses a cell preparation targeting bone metastatic tumor cells, its preparation method, and its application, belonging to the field of biomedical technology. The cell preparation comprises senescent neutrophils and drug-loaded cationic liposomes internalized within them. The cationic liposomes encapsulate a STING agonist and a pan-photokinase inhibitor. The preparation method includes: preparing drug-loaded liposomes using a thin-film dispersion-ultrasound method; obtaining senescent neutrophils through in vitro culture of extracted neutrophils; and preparing a senescent neutrophil preparation loaded with liposomes. This invention utilizes the natural bone marrow homing ability of senescent neutrophils to achieve precise targeting of bone metastatic tumor cells, and co-delivers two drugs through liposomes, simultaneously activating anti-tumor immunity and inducing tumor cell apoptosis / autophagy, synergistically treating bone metastases. This system has high drug loading capacity, good encapsulation efficiency, and sustained-release effect, and the preparation process is simple and controllable, providing a new strategy for the treatment of cancer bone metastases.

Disclosed herein is a method of providing an anti-cancer immunity in a subject with a bone metastatic cancer. The method involves co-administering to the subject an effective amount of a gamma-delta T cell stimulating agent and an effective amount of a γδ CAR T cell that binds a tumor antigen. Also disclosed herein is a recombinant T cell that expresses a gamma-delta T cell receptor (TCR) and a chimeric antigen receptor (CAR) polypeptide.

The invention relates to the technical field of focused ultrasound, in particular to a focused ultrasound path optimization method and system for a tumor bone metastasis focus. The method comprises the following steps: firstly, acquiring each candidate sound beam path of a transducer array and a unit path comprising each transducer; further obtaining an energy consumption coefficient according to the spatial distribution and acoustic resistance of voxels on the target path; further obtaining a damage coefficient according to the normal vector deviation corresponding to each skeleton interface voxel on the target path in combination with the spatial distribution of the skeleton interface voxels; further obtaining the path optimization degree according to the overall distribution of the energy consumption coefficient and the damage coefficient; and finally, selecting an optimal sound beam path based on the path optimization degree. According to the method, the energy consumption of each candidate sound beam path and the bone interface injury risk are quantified, the path optimization degree is comprehensively evaluated, automatic optimization of safe and efficient paths in bone metastasis focus focused ultrasound treatment is achieved, and the problem that in the prior art, a multi-path comprehensive optimization mechanism is lacked is solved.

The invention is suitable for the technical field of biological medicine, and provides a preparation method and application of a high heat treatment cell drug delivery system. Mitoxantrone (MTX) is loaded in human umbilical cord mesenchymal stem cells (PD-MSCs) derived on the basis of high heat treatment to prepare the drug delivery system PD-MTX, drugs can be accurately delivered to tumor sites, release is controlled through a pH sensitive mechanism, the treatment effect is improved, and the side effects of chemotherapy are reduced. The PD-MSCs are inactivated through high heat treatment, so that the safety is ensured. PD-MTX and alphaPD-L1 are combined for use, so that a synergistic effect of chemotherapy and immunization is formed, and accurate and safe treatment is realized. The method for high heat treatment of cells and drug loading is not limited to human umbilical cord mesenchymal stem cells and mitoxantrone, and can be popularized to other cells and drugs. The composition has a remarkable effect in treatment of prostatic cancer and prostatic cancer osseous metastasis, can be popularized to treatment of other diseases, and has wide application potential.

The invention belongs to the field of nuclear medicine imaging agents, and relates to an LAT1 targeted phosphoramidated tyrosine PET molecular probe as well as a preparation method and application thereof. The probe has a structure as shown in a formula I. The LAT1-targeted phosphoramidated tyrosine PET molecular probe provided by the invention can be used for high-specificity uptake of bones, and has excellent in-vivo metabolism performance and bone uptake retention capacity. The targeted PET molecular probe provided by the invention has a clear tumor ratio, can be rapidly metabolized out of a body through a kidney, and has important application value for early and accurate diagnosis of bone tumors and bone metastatic tumors.

The invention belongs to the field of biological medicine, and particularly relates to a preparation for targeted therapy of prostatic cancer osseous metastasis. The formulations provided herein include at least one of a nucleic acid encoding a protein, a vector, a cell, and a lipid nanoparticle RNA complex. The preparation can effectively inhibit the progress of the prostate cancer osseous metastasis, and provides a new direction for the treatment of the prostate cancer osseous metastasis.

The invention discloses a system for identifying multiple myeloma and bone metastatic tumor based on 18F-FDG PET / CT parameters. The system comprises a data acquisition module, a scoring model calculation module and an evaluation module. The data acquisition module is used for acquiring 18F-FDG PET / CT parameters of a patient as characteristic values, the scoring model is used for calculating a judgment score of the characteristic values by adopting a linear regression model, and the evaluation module is used for acquiring an identification result by adopting a threshold value method according to the judgment score and outputting the identification result to a user. By adopting the system, whether the patient is the multiple myeloma can be quickly evaluated, medical staff can be helped to identify and judge different disease patients with similar symptoms, and high-risk patients with the multiple myeloma or patients with the multiple myeloma can be quickly identified.

The present invention relates to the field of radiopharmaceutical chemistry, and more particularly to a radioactive probe that targets fibroblast activation protein (FAP), a preparation method, and applications thereof. The structural formula of the compound targeting FAP provided by the present invention is: #imgabs0#. This compound possesses excellent radionuclide labeling properties. The resulting radioactive probe, a FAP inhibitor, can simultaneously target tumor-associated fibroblast activation protein (FAP) and bone metabolism-related targets, thereby improving diagnostic accuracy and specificity, increasing retention time and effectiveness, and enhancing treatment outcomes. This allows for more comprehensive diagnosis and evaluation of tumors and bone metastases, and is particularly suitable for patients with both primary tumors and bone metastases.

The invention discloses a preparation method and application of a bone metastatic tumor organoid model, and belongs to the technical field of biology. The preparation method comprises the following steps: selecting an epithelial tumor cell line as a seed cell; preparing a natural structure bone matrix scaffold material; the prepared bone matrix scaffold material is subjected to pore diameter measurement, a scaffold with qualified pore diameter groups is reserved, an unqualified scaffold is eliminated, and the optimized scaffold material is soaked in gel to be attached; and putting the qualified bone matrix scaffold material into a culture container, uniformly inoculating the epithelium-derived tumor cell suspension on the surface of the bone matrix scaffold material, and carrying out static culture for 2-3 weeks to generate the bone metastatic tumor organoid model. The bone metastatic tumor organoid model prepared by the invention is applied to physical and drug therapy experiments and research on molecular mechanisms of bone metastasis.